News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Neurocrine Biosciences to Present Clinical Plan for NBI-34060 for Insomnia At the Salomon Smith Barney Health Care Conference 2001 (PR Newswire) ... largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis,... - Oct 26 4:13 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/011026/laf063_1.html

Posted on: 10/26/2001

"Yahoo - Neurocrine Biosciences to Present Clinical Plan for NBI-34060 for Insomnia At the Salomon Smith Barney Health Care Conference 2001"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quote
NBIX44.60+4.20
delayed 20 mins - disclaimer
Quote Data provided by Reuters

Friday October 26, 4:13 pm Eastern Time

Press Release

SOURCE: Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present Clinical Plan for NBI-34060 for Insomnia At the Salomon Smith Barney Health Care Conference 2001

Presentation May Be Accessed on Live Webcast

SAN DIEGO, Oct. 26 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - news) announced today that the Company will be presenting at the Salomon Smith Barney 2001 Health Care Conference being held in New York on Monday, October 29, 2001 at 3:30PM Eastern Time (12:30PM Pacific Time). The presentation will be simultaneously Webcast and participants may access the Webcast through the Internet via a link provided by Salomon Smith Barney at http://www.veracast.com/clientaccess/ssb/healthcare-2001/36114457.cfm or through a link provided via the Company's website at http://www.neurocrine.com.

Gary Lyons, President and CEO of Neurocrine will focus his presentation on the insomnia program. If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600 and ask for Claudia Jones or Elizabeth Foster. The presentation will be archived for 30 days.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.

SOURCE: Neurocrine Biosciences, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Neurocrine Biosciences Inc (NasdaqNM:NBIX - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740